Edward Garmey

Edward Garmey has extensive work experience in the field of medical oncology consulting and leadership. Edward is currently serving as the Interim CMO at HiFiBiO Therapeutics. Edward also works as a Consulting CMO at ModeX Therapeutics Inc, where they collaborate with the team on the development of cancer medicines that target multiple protein structures simultaneously. Additionally, Edward is a Consultant CMO at Tagworks Pharmaceuticals, ImmunoMet Therapeutics, Inc., GigaGen Inc, Oncoheroes Biosciences, Linnaeus Therapeutics, and ImmuneSensor Therapeutics.

Moreover, Edward founded CMO Consulting, Inc. in 2018, a company that provides clinical drug development consulting services to the biopharmaceutical industry. Prior to their consulting work, they served as a Visiting Instructor in the Therapeutics Graduate Program at Harvard Medical School. Overall, Edward Garmey's expertise lies in strategic clinical drug development, CMO leadership, and the application of innovative therapies in oncology.

Edward Garmey holds an AB degree from Harvard University. Edward also received an M.D. degree from Icahn School of Medicine at Mount Sinai. The specific years of completion for both degrees are not provided.